Analysts' Actions: ARIA, EA, HGSI, BBBY
NEW YORK (TheStreet) -- CHANGE IN RATINGS
Ariad Pharmaceutical(ARIA) was initiated with a Buy rating at UBS. $20 price target. Near-term driver of phase I/II date from AP26113, UBS said.
Bed Bath & Beyond(BBBY) was downgraded at Canaccord Genuity from Buy to Hold. $73 price target. Company is losing market share, Canaccord said.
Bill Barrett(BBG) was initiated with a Hold rating at Deutsche Bank. $30 price target. Company remains highly leveraged to natural gas, Deutsche said.
BioMarin(BMRN) was initiated with a Buy rating at UBS. $43 price target. GALNS can be a $500 million product, UBS said.
Electronic Arts(EA) was initiated with a Neutral rating at Ascendiant. $16 price target. Concerns remain around industry growth and the company's key games, Ascendiant said.
Human Genome(HGSI) was initiated with a Neutral rating at UBS. $8 price target. Company will continue to trade on monthly IMS sales for Benlysta, UBS said.
IDT Corp.(IDT) was upgraded to hold at TheStreet Ratings.
MAP Pharmaceuticals(MAPP) was downgraded to sell at TheStreet Ratings.
MercadoLibre(MELI) was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $93 price target, Goldman said.
Mattress Firm(MFRM) was initiated with a Hold rating at Stifel Nicolaus. Valuation call, as the stock is up 132% since its IPO.
Packaging Corp.(PKG) was upgraded at JP Morgan from Underweight to Neutral. Company continues to execute well.
AT&T(T) was upgraded at JP Morgan to Overweight from Neutral. $33 price target. Higher tablet demand should drive ARPU growth, JP Morgan said.
United Therapeutics(UTHR) was downgraded at Leerink Swann to Market Perform. Company is facing increased generic risk, Leerink Swann said.
Whiting Petroleum(WLL) was initiated with a Buy rating at Brean Murray. $70 price target. Company was also placed on the Focus List. Company should deliver more consistent drilling results, Brean Murray said.
Stock Comments / EPS Changes
Apple(AAPL) estimates, target were increased at Credit Suisse. Estimates were raised through 2013. Company is seeing higher iPhone sales, Credit Suisse said. Outperform rating and new $750 price target.